Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
Authors:
- Kazuya KariyamaKKKazuya Kariyama
- Kazuhiro NousoKazuhiro Nouso
- Atsushi HiraokaAHAtsushi Hiraoka
- Fujimasa TadaFTFujimasa Tada
- Hideko OhamaHOHideko Ohama
- Hidenori ToyodaHTHidenori Toyoda
- Satoshi YasudaSYSatoshi Yasuda
- Toshifumi TadaToshifumi Tada
- Kazunari TanakaKTKazunari Tanaka
- Kunihiko TsujiKTKunihiko Tsuji
- Ei ItobayashiEIEi Itobayashi
- Akemi TsutsuiATAkemi Tsutsui
- 11 November 2025
- journal article
- Published by Wiley in Hepatology Research
- Vol. 56 (3) , 351-358
Abstract
Background and Aims: Hepatocellular carcinoma (HCC) management has markedly evolved in Japan. We evaluated temporal changes in patient characteristics and outcomes between 2004–2013 and 2014–2023. Methods: In this multicenter retrospective study, 7275 treatment‐naïve HCC patients were analyzed (3832 vs. 3443). Propensity score matching (PSM) for age, sex, albumin‐bilirubin (ALBI) score, and viral status yielded 4754 patients. Overall survival (OS) was compared by the Barcelona Clinic Liver Cancer (BCLC) stage and treatment modality. Cox regression identified independent prognostic factors. Results: After PSM, baseline characteristics were balanced. OS significantly improved in BCLC‐0/A patients in 2014–2023 ( p < 0.0001), but not in BCLC‐B, C, or D. Among BCLC‐A patients, surgical resection ( p = 0.0042) and ablation ( p = 0.0019) showed improved outcomes in the recent era, whereas TACE and systemic therapy did not. Subgroup analysis revealed survival gains were confined to viral HCC, with minimal improvement in nonviral HCC. Multivariate analysis confirmed the recent era (HR 0.800, 95%CI 0.658–0.972, p = 0.025), curative therapy, and ALBI score as independent prognostic factors. Conclusions: Survival outcomes in Japan improved primarily for early‐stage viral HCC, reflecting advances in curative treatments and antiviral management. Nonviral HCC showed minimal improvement, highlighting the need for novel therapeutic strategies for this growing population. Clinical trial registration: This study is a retrospective study using anonymized database data, and clinical trial registration was not performed.Keywords
This publication has 18 references indexed in Scilit:
- Safety and Efficacy of Robotic vs Open Liver Resection for Hepatocellular CarcinomaJAMA Surgery, 2023
- Improved survival of viral hepatocellular carcinoma but not non‐viral hepatocellular carcinoma from 2000 to 2020: A multi‐centre cohort study of 6007 patients from high‐volume academic centres in JapanAlimentary Pharmacology & Therapeutics, 2022
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Epidemiology and surveillance for hepatocellular carcinoma: New trendsJournal of Hepatology, 2020
- Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA LevelsAnnals of Surgery, 2018
- Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infectionJournal of Medical Virology, 2016
- Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in JapanLiver Cancer, 2016
- Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study fromJapanHepatology Research, 2015
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008